Applied StemCell, an advanced therapeutics CRO/CDMO specializing in iPSCs, gene editing, and small animal models, announced today that it has submitted a Type II Drug Master File (DMF) to the U.S.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback